Sentences with phrase «austerity program in»

In response to the dawn of the financial crisis, in 2010 the Greek government along with Troika (European Union (EU), the International Monetary Fund (IMF) and the European Central Bank (ECB) introduced a strict austerity program in order to receive its first bailout loan.

Even with austerity programs in place, the eurozone's collective budget deficit this year will exceed 4.5 % of GDP.

The accompanying chart shows the incredible impact of the ongoing austerity programs in Europe.

Not exact matches

But to the government's credit, it has hit most of its spending targets in the first few years of the austerity program Flaherty.

As Globe columnist Neil Reynolds recently noted, the IMF has called on the United States and Europe to abandon austerity programs before either had put any in place.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The irony is that while Russia is being told that taking this advice will help make it an American - style economy, Republican congressmen in the United States have been denouncing the IMF and its austerity programs.

For weaker economies in the euro zone that are seeing subdued domestic demand as a result of austerity programs, there were also encouraging signs in the trade figures for August.

From New York City's bankruptcy to Puerto Rico's insolvency and Third World debtors subjected to IMF «austerity programs,» national bankruptcies shift control to centralized financial planners in what Naomi Klein has called Crisis Capitalism.

But as cities, counties and states compete for economic development, spending on such programs nationwide has climbed into the billions of dollars, even in an era of fiscal austerity.

If you didn't major in economics or you have no clue what austerity means, read on to find out how this fiscal program works.

Growth in most of the eurozone has remained tepid and reliant on continued central bank stimulus, though the European Central Bank's (ECB's) bond - purchasing program has been hampered by a scarcity of eligible bonds, as issuance from member governments is restricted by their austerity - driven policies.

In Syriza's case, for example, it campaigned on a promise to end the former administration's austerity programs.

But it has engaged in some austerity programs.

Prior to the legislature's proposal for increased taxes, Vanderhoef had presented an austerity budget that called for the immediate sale of Summit Park as well as massive cuts in many other programs.

A ComRes poll for today's Independent has shown that 72 % of the public would like to see a change in the government's flagship austerity program.

Some economists want to claim that austerity measures HAVE been tried, and, since we're still in a recession / depression, austerity is therefore a failed «research program» / economic practice.

Obama intended the prospect of the fiscal cliff's dramatic mandatory cuts in social programs to extort progressive Congressional Democrats into agreeing to inflict severe austerity by voting in favor of what Obama hoped would be massive cuts in social programs and the safety net adopted by the Congressional «super committee» created by the same bipartisan austerity deal that created the «fiscal cliff.»

Stuckler and Basu argue that the harsh austerity measures and cutting of social programs adopted in response to the recent financial crisis have exacerbated public health problems and cost thousands of lives.

Carr also explained that local school districts aggressively engage in competitive grant programs because in a time of austerity, it's imperative they find other revenue streams to support the needs of their traditional public schools.

While Chinese President Xi Jinping's austerity program and anti-corruption drive have hurt sales of everything from Rolex watches to first growth Bordeaux wines in Hong Kong, the top end of the art market is thriving.

Budget austerity is running rampant through Congress and no program — whether it's vital investments in economic growth or not — is safe.

Akin Gump Strauss Hauer & Feld, where RPL rose 12.9 percent, to $ 965,000, spent much of 2008 in an austerity program, eventually shedding 56 partners, a 16.9 percent reduction.